

Hypertension in People With HIV

Chris Longenecker, MD
Professor of Medicine & Global Health
Werner E. Samson Endowed Professorship in Cardiology
University of Washington School of Medicine

Last Updated: July 19, 2025



Disclosures

Gilead Sciences: Advisory Board



Disclaimer

Funding for this presentation was made possible by 5 TR7HA53202-02-00 from the Human Resources and Services Administration HIV/AIDS Bureau. The views expressed do not necessarily reflect the official policies of the Department of Health and Human Services nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government. *Any trade/brand names for products mentioned during this presentation are for training and identification purposes only.*



Disclaimer

New AHA/ACC Guidelines Coming Out Next Month!

AHA Target BP: Webinar on 8/28/25 10am PDT

https://targetbp.org/event/target-bp-guideline-webinar/




Highlights of new guidelines will include

- Blood pressure thresholds for diagnosis and treatment of high blood pressure
- Cardiovascular and cognitive risks of uncontrolled high blood pressure
- Calculation of cardiovascular disease risk as part of diagnostic and treatment approach
- Utilization of recommended medication classes in combination pill form to improve control and adherence




HIV is a risk factor for cardiovascular disease








North American AIDS Cohort Collaboration on Research and Design











It's Time to Extend the HIV Treatment Cascade




ASCVD Prevention Diagnose Appropriately Manage Reach BP Cholesterol






"I always thought I'd die of AIDS"



Perceived Susceptibility to CVD


Who does primary prevention for PWH?







Blood pressure control may depend on who is managing it





MAJOR ARTICLE







Should Human Immunodeficiency Virus Specialty Clinics Treat Patients With Hypertension or Refer to Primary Care? An Analysis of Treatment Outcomes

A. Ben Appenheimer, ^{1,2} Barbara Bokhour, ^{3,4} D. Keith McInnes, ^{3,4} Kelly K. Richardson, ¹ Andrew L. Thurman, ¹ Brice F. Beck, ¹ Mary Vaughan-Sarrazin, ^{1,2} Steven M. Asch, ^{5,6} Amanda M. Midboe, ⁶ Thom Taylor, ⁶ Kelly Dvorin, ⁴ Allen L. Gifford, ^{3,4} and Michael E. Ohl^{1,2}

¹Center for Comprehensive Access and Delivery Research and Evaluation, Iowa City VA Medical Center, Iowa; ²Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City; ³Boston University School of Public Health, Department of Health Law, Policy, and Management, Massachusetts; ⁴Center for Healthcare Organization and Implementation Research, Edith Nourse Rogers Memorial VA Healthcare System, Bedford, Massachusetts; ⁵Division of General Medical Science, Department of Medicine, Stanford University School of Medicine, Palo Alto, California: ⁶Center for Innovation to Implementation, VA Palo Alto Health Care System, Palo Alto, California

Table 2. Clinic Characteristics by Hypertension Delivery Model, N = 73 Clinics^a

Facility Characteristic	Overall (n = 73)	Hypertension Delivery		
		Consolidated Care (n = 42)	Shared Care (n = 31)	
Patient volume, mean (STD)	256 (230)	330 (262)	157 (124)	
Multidisciplinary team, n (%)	39 (53.4)	30 (71.4)	9 (29.0)	
Case Manager, n (%)	16 (21.9)	12 (28.6)	4 (12.9)	
Educator, n (%)	17 (23.3)	14 (33.3)	3 (9.7)	
Pharmacist, n (%)	49 (67.1)	30 (71.4)	19 (61.3)	

Table 4. Hypertension Control by Clinic Characteristics, N = 5794 Patients

Clinic Characteristic	Number of Patients (%)	Percent With Controlled Blood Pressure (%)	<i>P</i> Value
Hypertension Delivery			<.01
Consolidated care	4566 (78.8)	65.6	
Shared care	1228 (21.2)	59.4	
Multidisciplinary Team			.31
Yes	4205 (72.6)	64.9	
No	1179 (20.3)	62.2	
Indeterminate	276 (4.8)	60.1	
Missing	134 (2.3)	73.9	
Case Manager			.76
Yes	1218 (21.0)	66.0	
No	3942 (68.0)	64.3	
Indeterminate	322 (5.6)	62.4	
Missing	312 (5.4)	59.6	
Educator			.70
Yes	1660 (28.6)	66.2	
No	3193 (55.1)	63.5	
Indeterminate	629 (10.9)	65.5	
Missing	312 (5.4)	59.6	
Pharmacist			.95
Yes	4533 (78.2)	64.1	
No	757 (13.1)	64.9	
Indeterminate	504 (8.7)	65.1	
Missing	0 (0.0)	0.0	



Original Investigation | Infectious Diseases

March 5, 2024

Nurse-Led Strategy to Improve Blood Pressure and Cholesterol Level Among People With HIV

A Randomized Clinical Trial

Christopher T. Longenecker, MD¹; Kelley A. Jones, PhD²; Corrilynn O. Hileman, MD^{3,4}; et al.


» Author Affiliations | Article Information


JAMA Netw Open. 2024;7(3):e2356445. doi:10.1001/jamanetworkopen.2023.56445













Diagnosis of Hypertension in PWH



Blood Pressure Categories




BLOOD PRESSURE CATEGORY	SYSTOLIC mm Hg (upper number)		DIASTOLIC mm Hg (lower number)
NORMAL	LESS THAN 120	and	LESS THAN 80
ELEVATED	120 – 129	and	LESS THAN 80
HIGH BLOOD PRESSURE (HYPERTENSION) STAGE 1	130 – 139	or	80 – 89
HIGH BLOOD PRESSURE (HYPERTENSION) STAGE 2	140 OR HIGHER	or	90 OR HIGHER
HYPERTENSIVE CRISIS (consult your doctor immediately)	HIGHER THAN 180	and/or	HIGHER THAN 120



Hypertension Diagnosis Pearls

- Develop a workflow for the clinic that encourages accurate BP measurement
- Automatic oscillometric BP machines more accurate than manual
- AHA materials are helpful to remind staff of accurate BP measurement principles
- Learn how to enter home BP data in the EMR





Hypertension Diagnosis Pearls

Home blood pressures

- HBPM vs. ABPM
- www.validatebp.org/
- Home BP is on average
 ~5mmHg less than
 office measured BP


Check for LVH on echo or ECG

 If none, it is unlikely that the hypertension is severe and/or longstanding





Secondary Causes of Hypertension






Treatment of Hypertension in PWH




Who should be treated for high blood pressure?







EXTRA-CVD Treatment Algorithm





Initiation of BB associated with worse outcomes in PWH






Beta-blockers associated with 90% increased risk of incident CVD (vs. ACE/ARB)



Blood pressure change and treatment emergent hypertension on modern ART: data from the ADVANCE trial




Differences between regimens were attenuated after adjustment for changes in BMI



Hypertension management and ART pearls

- ART raises blood pressure
 - Differences between drugs/regimens is extremely modest
- Hypertension rarely merits switch in ART
- Beware clinically relevant drug interactions with boosted ART
 - Amlodipine (modest)
 - Carvedilol (weak)



Quality of evidence: Very Low (i)

Summary:

Coadministration has not been studied. Amlodipine is metabolized by CYP3A4. Darunavir/cobicistat could potentially increase amlodipine exposure. Caution is warranted and clinical monitoring of therapeutic and adverse effects is recommended. Amlodipine should be started at low doses with careful titration to response.

Description:

Based on theoretical considerations darunavir/cobicistat is expected to increase amlodipine plasma concentrations (CYP3A and/or CYP2D6 inhibition). Clinical monitoring of therapeutic and adverse effects is recommended when these medicines are co-administered with darunavir/cobicistat.

Rezolsta Summary of Product Characteristics, Janssen-Cilag Ltd, July 2023.

Coadministration is expected to increase concentrations of amlodipine. Clinical monitoring is recommended for co-administration with calcium channel blockers metabolized by CYP3A.

Prezcobix US Prescribing Information, Janssen Pharmaceuticals Inc, March 2023.



Conclusions

- Together with smoking and dyslipidemia, hypertension is a significant driver of cardiovascular risk among PWH
- Unique barriers to hypertension diagnosis and management exist in US HIV clinics
- Blood pressure self-monitoring at home is effective but underutilized.
- The American Heart Association has excellent resources for hypertension management
 - Look out for new guidelines coming out soon!



Acknowledgment

This Mountain West AIDS Education and Training (MWAETC) program is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of award 5 TR7HA53202-02-00 totaling \$1,410,386 with 0% financed with non-governmental sources.

The content in this presentation are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, HRSA, HHS, or the U.S. Government.

